Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03573518 · ClinicalTrials.gov registry record · Phase 2
Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris
A Phase 2 study, sponsored by Botanix Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 368
- Enrollment target
NCT03573518 is a Phase 2 study that has completed, run by Botanix Pharmaceuticals. The registered enrollment target is 368 participants.
The verdict
NCT03573518, a Phase 2 study, has completed, sponsored by Botanix Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 368 participants
- Enrollment target
Study Summary
The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
Interventions
- DRUG Vehicle
- DRUG BTX 1503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2018-06-26 |
| Est. Completion | 2019-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03573518
The ClinicalTrials.gov registry entry for NCT03573518 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Botanix Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03573518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03573518 about?
NCT03573518 is a clinical study titled "Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris". The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
What is the current status of trial NCT03573518?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 368 participants. The study started on 2018-06-26. Estimated completion is 2019-09-05.
What interventions are being tested in trial NCT03573518?
The interventions under investigation include: Vehicle (DRUG), BTX 1503 (DRUG).
Who is sponsoring clinical trial NCT03573518?
This trial is sponsored by Botanix Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.